ClinicalTrials.gg
CompletedNCT06963580Updated Jun 25, 2026

Efficacy of MI078 Capsules in Treating Postpartum Depression

A Phase 2 interventional study of MI078 capsule dose 1 and MI078 capsule dose 2 in Postpartum Depression, sponsored by Nanjing Minova Pharmaceutical Co., Ltd.. Completed at 21 sites in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Nanjing Minova Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Sep 2024, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Depression, Postpartum with a site in China — 9 open to participants now, 10 under way, 1 of them phase 3. Depression, Postpartum · China.

Enrollment
16th of 17
72 · median 270
Started
2024
with 1 other
Phase 2
Only one
of the 20
Registered
14th of 20
by date
Lead sponsor
3 of 20
Nanjing Minova Pharmaceutical Co., Ltd.

Among the 20 studies in Depression, Postpartum with a site in China, this one is the 16th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 2, and was the 14th registered.

Depression, Postpartum

569 studies on the registry are indexed under Depression, Postpartum; 134 are open to participants now.

Browse Depression, Postpartum studies →

Open to participants now

9 of the 20 studies in Depression, Postpartum with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 87 Depression, Postpartum studies recruiting now, 54 (62%) set no upper age limit and 30 (34%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Depression, Postpartum with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, double-blind, placebo-controlled trial. It includes three groups. Each group will enroll 24 participants. The trial aims todetermine: To evaluate the efficacy of MI078 capsules in treating postpartum depression and to explore the optimal dosing regimen for MI078 capsules.

To assess the safety of MI078 capsules in postpartum depression patients.

Read the detailed description

This study employs a multicenter, randomized, double-blind, placebo-controlled parallel design. It plans to include three groups: one for the test drug at dose 1, one for the test drug at dose 2, and one for the placebo group, with 24 subjects in each group. The study consists of a screening period (D-14 to D-1), a treatment period (Day 1 to Day 4), and a follow-up period (Day 5 to Day 31). Enrolled subjects will be randomly assigned in a 1:1:1 ratio and will take the study medication for a total of 3 days.

03

Conditions studied

  • Postpartum Depression
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18 to 45 years (inclusive) with a (BMI) ranging from 18.5 to 37.0 kg/m² (inclusive).
  • The patient meets the diagnostic criteria for Major Depressive Disorder (MDD) as defined in the (DSM-5), based on the investigator's clinical evaluation. The onset of illness must occur between 28 weeks of pregnancy and 4 weeks postpartum (inclusive).
  • The patient is within 9 months postpartum during the screening period.
  • The total score on the HAMD17 is ≥26 during both the screening and baseline periods.
  • The patient understands and voluntarily agrees to participate in the study, consents to comply with all study requirements, and is able to provide written prior to the initiation of any study-specific procedures.
  • The patient is able to communicate effectively with the investigator, is willing and able to adhere to the lifestyle restrictions or requirements specified in the study protocol, and can cooperate fully in completing the trial.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of another mental disorder according to criteria, as assessed by the investigator
  • History of bipolar disorder, schizophrenia, and/or schizoaffective disorder
  • History of sleep apnea
  • Presence of suicidal ideation/intent, or a score >3 on Item 3 (suicide) of the HAMD17, or a response of "yes" to Item 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) within the past 6 months, or a history of suicidal behavior within the past year
  • Meeting the diagnostic criteria for treatment-resistant depression
  • Continuous use of therapeutic doses of antidepressants for more than 14 days during the current episode
  • Failure to discontinue psychotropic medications for at least 5 half-lives prior to the use of the study drug.
  • Need for concurrent use of other psychotropic medications, such as antidepressants, antipsychotics, mood stabilizers, and sedative-hypnotics (excluding benzodiazepines), during the trial dosing period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    MI078 capsule dose 1

    MI078 capsule dose 1

    Drug: MI078 capsule dose 1

  • Experimental
    MI078 capsule dose 2

    MI078 capsule dose 2

    Drug: MI078 capsule dose 2

  • Placebo comparator
    placebo

    Placebo of MI078 capsules

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in HAM-D17 total score

    The Seventeen-Item Hamilton Rating Scale for Depression (HAM-D17) contains 17 individual ratings related to the following symptoms: depressed mood, feelings of guilt, suicide, insomnia (initial, middle, and late), work and interests, psychomotor retardation, psychomotor agitation, anxiety (psychic and somatic), gastrointestinal symptoms, general somatic symptoms, sexual interest, hypochondriasis, insight, and weight loss. The total score ranges from 0 to 52, with higher scores indicating more severe depression.

    Time frame: up to day 31

Secondary outcomes

  1. HAM-D17 response

    Defined as having a 50% or greater reduction from baseline in HAM-D17 total score. The total score ranges from 0 to 52, with higher scores indicating more severe depression.

    Time frame: up to day 31

  2. HAM-D17 remission

    Defined as having a HAM-D17 total score ≤7. The total score ranges from 0 to 52, with higher scores indicating more severe depression

    Time frame: up to day 31

  3. Change from baseline in the CGI-S score

    The CGI-S scale is a 7-point scale that requires the Investigator to assess how mentally ill is the patient at this time. 1 - normal, not at all ill; 2 - borderline mentally ill; 3 - mildly ill; 4 - moderately ill; 5 - markedly ill; 6 - severely ill; or 7 - among the most extremely ill patients

    Time frame: up to day 31

  4. Clinical Global Impression - Improvement (CGI-I) scale positive response

    The CGI-I scale is a 7-point scale that requires the Investigator to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of study drug treatment. 1 - very much improved; 2 - much improved; 3 - minimally improved; 4 - no change; 5 - minimally worse; 6 - much worse; or 7 - very much worse

    Time frame: up to day 31

  5. Change from baseline in MADRS total score

    The MADRS contains 10 individual items related to the following symptoms: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The total score ranges from 0 to 60, with higher scores indicating more severe depression

    Time frame: up to day 31

  6. Change from baseline in Edinburgh Postnatal Depression Scale (EPDS) total score

    The Edinburgh Postnatal Depression Scale (EPDS) is a set of 10 screening questions. The total score ranges from 0 to 30, with higher scores indicating more severe depression.

    Time frame: up to day 31

  7. Change from baseline in Hamilton Anxiety Rating Scale (HAM-A) total score

    The HAM-A contains 14 individual ratings related to the following symptoms: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic (muscular), somatic (sensory), cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview. The total score ranges from 0 to 56, with higher scores indicating more severe anxiety.

    Time frame: up to day 31

  8. Safety Evaluation Indicators

    Adverse events (AEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), clinical laboratory test, 12-lead electrocardiogram (ECG),C-SSRS,PWC-20

    Time frame: up to day 31

07

Study locations

21 sites
  • The Affiliated Beijing Anding Hospital of Capital Medical University, Wuhu Hospital
    Wuhu, Anhui 241000, China
  • Beijing HuiLongGuan Hospital
    Beijing, Beijing Municipality 100096, China
  • Xiamen Xian Yue Hospital
    Xiamen, Fujian, China
  • Shunde Hospital of Southern Medical University
    Foshan, Guangdong 528308, China
  • The First Affiliated Hospital of Jinan University
    Guangzhou, Guangdong 510630, China
  • Guangxi Zhuang Autonomous Region People's Hospital
    Nanning, Guangxi 530021, China
  • The People's Hospital of Guizhou Province
    Guiyang, Guizhou 550002, China
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050023, China
  • Xingtai People's Hospital
    Xingtai, Hebei 054001, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • Shanghai Mental Health Center
    Shanghai, Shanghai Municipality 200122, China
  • Shanghai Pudong New Area Mental Health Center
    Shanghai, Shanghai Municipality 200124, China
  • Linfen Central Hospital
    Linfen, Shanxi 041000, China
  • The First Hospital of Shanxi Medical University
    Taiyuan, Shanxi 030001, China
  • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
  • First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
  • The First People's Hospital of Hangzhou
    Hangzhou, Zhejiang 310006, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
  • The Affiliated Kangning Hospital of Ningbo University
    Ningbo, Zhejiang 315201, China
  • The First Affiliated Hospital of Ningbo University
    Ningbo, Zhejiang, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Aug 2025, 10 months.

Of 14 phase 2 interventional studies under Depression, Postpartum, half reached primary completion within 17 months of starting (the median); a quarter within 10 and three quarters within 30. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 9, 2025
StartActual
Sep 9, 2024
Primary completionActual
Aug 7, 2025
CompletionActual
Aug 7, 2025
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06963580
Lead sponsor
Nanjing Minova Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
May 9, 2025
Start date
Sep 9, 2024
Primary completion
Aug 7, 2025
Completion
Aug 7, 2025
Last update
Jun 25, 2026

Study contacts

huafang Li
study chair · Shanghai Mental Health Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MI078

Start the discussion